Maintaining treatment with CDK4/6 inhibitors significantly suppresses the growth of breast cancer cells, even after drug resistance has developed, according to new research.

Trilaciclib significantly reduced chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer, which ...

Most of the time, you’re going to give 1 cycle of R-ICE [rituximab, ifosfamide, carboplatin, and etoposide] or R-GemOx…. We’re not going to reevaluate this patient after 1 or 2 cycles of R-GemOx. The ...

While the DeFi boom of 2020 catalyzed the broader blockchain ecosystem, this cycle may take a more evolved and measured approach, emphasizing utility and long-term sustainability. DeFi has ...

CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising ...

Record temperatures last year pushed the global water cycle to “new climatic extremes,” according to the Global Water Monitor 2024 report. The document, produced by an international consortium ...

Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, ...

Currently, there are three CDK4/6 inhibitors approved to treat breast cancer at different stages — Ibrance (chemical name: palbociclib), Kisqali (chemical name: ribociclib), and Verzenio (chemical ...

Understanding the dynamics and stability of these marks through the cell cycle is crucial in maintaining a given chromatin state. Recent research has highlighted DNA methylation as a bona fide ...